You are viewing an archive version of the PSNC website taken on 18th April 2013. This site is not updated, and may be out of date or relate to old NHS structures.
For updated and current information, please visit our new website at www.psnc.org.uk
Skip Navigation
PSNC Home Page
Advanced Search
.

Pharmaceutical Services Negotiating Committee

General News

Tredaptive 1000mg/20mg modified-release tablets - Availability suspended

MSD have announced the company is taking steps to suspend the availability of Tredaptive 1000mg/20mg modified-release tablets worldwide.

MSD is recommending that physicians stop prescribing Tredaptive. MSD is also recommending that physicians review treatment plans for patients taking Tredaptive in a timely manner to discontinue Tredaptive, and consider other changes in therapy to achieve their dyslipidemia management goals. In the meantime, MSD encourages patients with questions to speak with their health care provider, and to not discontinue therapy without first speaking with their physician.

MSD issued the following statement:

“Patients currently taking Tredaptive are our priority, and we are committed to continue to work with regulatory agencies around the world to ensure that physicians have appropriate information as we take steps to suspend the availability of Tredaptive,”

MSD released more detailed information here.

Posted 14 January 2013

< Back